Company Overview and News
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
ODP WBA LMAT YY
Ulta Beauty, Inc. (ULTA - Free Report) solid store-expansion efforts, adoption of new revenue standard, higher market share gains, sturdy e-commerce sales and salon operations bode well. Moreover, the company is on track with its loyalty program, which was one of the foremost sales growth drivers in second-quarter fiscal 2018. These efforts not only helped the company to deliver robust second-quarter results but also helped the stock to outpace the industry in the past three months.
Newpark Resources, Inc. (NR - Free Report) : This company that provides products, rentals, and services primarily to the oil and gas exploration and production industry has seen the Zacks Consensus Estimate for its current year earnings increasing 2.4% over the last 60 days.
ODP CONN NR WERN CHEF
Bed Bath & Beyond Inc. (BBBY - Free Report) is grappling with multiple headwinds like strained margins over past few quarters, soft comparable store sales (comps) and decline in number of store transactions. These factors have also hurt the company’s recently reported second-quarter fiscal 2018 results, wherein the top and bottom line lagged the estimates and the latter fell year over year. Following the dull quarterly results, management trimmed its fiscal 2018 guidance as well.
TSCO ODP FIVE BBBY
2018-10-01 zacks - 1
Shares of Tractor Supply Company (TSCO - Free Report) have displayed unprecedented growth in the past year and emerged as an attractive investment option. Notably, the stock surged 44.3% in a year, marking an outperformance compared with the industry’s growth of 18.4%.
TSCO 2454 ODP RGRNF FIVE RGS
GREENVILLE, Wis. and LOMBARD, Ill., Sept. 25, 2018 (GLOBE NEWSWIRE) -- School Specialty, Inc. (OTCQB:SCOO), home of the 21st Century Safe School™ and the leading provider of products and innovative services and solutions that support integrated learning environments for improved student social, emotional, mental and physical well-being, today announced the appointment of Stacey Rubin as its senior vice president of Marketing.
ODP TRBNW SCOO KHC TRCO TRBAB
Under legendary founder Martin Sorrell, most of the ad agencies under the WPP umbrella operated independently and even competed against each other for accounts; Sorrell resigned in April
ODP WPPGF WPPGY
Digitalisation des achats : Esker renforce son offre Purchase-to-Pay avec l'intégration des catalogues de fournisseurs externes
Shares of Office Depot, Inc. (ODP - Free Report) have surged roughly 46% in the past six months. This Zacks Rank #2 (Buy) stock has not only fared better than the industry that increased 21% but also the Zacks Retail & Wholesale Sector that advanced about 8%. The company’s business operating model, growth prospects and omni-channel capabilities have definitely acted as propellants. The company is trying all means to give itself a complete makeover in an environment where demand for office products (paper-based) has shrunk due to technological advancements.
TGT BURL ODP URBN
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
2018-09-17 zacks - 1
The Michaels Companies, Inc. (MIK - Free Report) has failed to impress investors on the sales front as its top line lagged estimates in 10 of the last 14 quarters, including second-quarter fiscal 2018. Also, the company’s dismal margins trend due to higher costs has been weighing on investors’ sentiments. In the past month, shares of this leading arts and crafts retailer have declined 16% against the industry’s 7% rally.
MIK TSCO ODP FIVE
Shares of Hibbett Sports, Inc. (HIBB - Free Report) have lost 21.1% in the past month due to lower-than-expected results in second-quarter fiscal 2019. Notably, this marked the company’s second straight top- and bottom-line miss. Also, trimmed guidance for the fiscal year is hurting investors’ sentiments. Meanwhile, the industry rallied 10.2% in the same period. The company incurred loss in the fiscal second quarter mainly due to higher SG&A expenses that weighed on operating margins.
TSCO ODP HIBB FIVE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ODP / Office Depot, Inc. on message board site Silicon Investor.
as of ET